BridgeBio Pharma (BBIO) Return on Assets (2019 - 2026)

BridgeBio Pharma's Return on Assets history runs 8 years deep, the most recent figure standing at 0.01% for Q1 2026.

• In Q1 2026, Return on Assets changed 0.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.01% (changed 0.0% YoY), while the FY2025 annual figure was 0.01%, changed 0.0% from the prior year.
• Return on Assets came in at 0.01% for Q1 2026 at BridgeBio Pharma, up from 0.01% in the prior quarter.
• In the past five years, Return on Assets ranged from a high of 0.01% in Q2 2024 to a low of 0.01% in Q4 2023.
• A 5-year average of 0.01% and a median of 0.01% in 2025 frame the typical range for Return on Assets.
• On a YoY basis, Return on Assets climbed as much as 0 bps in 2022 and fell as far as 0 bps in 2022.
• BridgeBio Pharma's Return on Assets stood at 0.01% in 2022, then dropped by 29 bps to 0.01% in 2023, then soared by 40 bps to 0.01% in 2024, then retreated by 6 bps to 0.01% in 2025, then gained by 17 bps to 0.01% in 2026.
• According to Business Quant data, Return on Assets over the past three periods registered 0.01%, 0.01%, and 0.01% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison